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Abstract
Background: Evaluation of evidence for the effectiveness of implementation strategies aimed at
reducing prescriptions for the use of acid suppressive drugs (ASD).
Methods: A systematic review of intervention studies with a design according to research quality
criteria and outcomes related to the effect of reduction of ASD medication retrieved from Medline,
Embase and the Cochrane Library. Outcome measures were the strategy of intervention, quality
of methodology and results of treatment to differences of ASD prescriptions and costs.
Results: The intervention varied from a single passive method to multiple active interactions with
GPs. Reports of study quality had shortcomings on subjects of data-analysis. Not all outcomes were
calculated but if so rction of prescriptions varied from 8% up to 40% and the cost effectiveness was
in some cases negative and in others positive. Few studies demonstrated good effects from the
interventions to reduce ASD.
Conclusion: Poor quality of some studies is limiting the evidence for effective interventions. Also
it is difficult to compare cost-effectiveness between studies. However, RCT studies demonstrate
that active interventions are required to reduce ASD volume. Larger multi-intervention studies are
necessary to evaluate the most successful intervention instruments.
Background
Analysis of the use of dyspeptic medication demonstrate
that acid-suppressive drugs (ASD) are prescribed in 10%
of the population each year [1-3]. Three percent of these
patients are chronic users (>180 DDD), mostly of Proton-
Pump Inhibitors (PPI), of which prescriptions increase
5% every year [4,5]. Together dyspeptic patients account
for almost 11% of the pharmaceutical budget of the pub-
lic insurance companies in the Netherlands. The Dutch
multi-disciplinary guideline on 'Dyspepsia management'
recommends PPI therapy for typical reflux symptoms for
a maximum of eight weeks [6]. Only severe oesophagitis
grade C/D requires long-term treatment with PPI. In most
other cases gradual termination is possible.
However, many physicians repeat prescriptions without
systematic evaluation of symptoms. Consequently Dutch
national prevalence data of oesophagitis do not match
with the rate of people using ASD, indicating that pre-
scription recommendations are not adequately imple-
mented [7-9].
Published: 5 November 2007
BMC Health Services Research 2007, 7:177 doi:10.1186/1472-6963-7-177
Received: 17 January 2007
Accepted: 5 November 2007
This article is available from: http://www.biomedcentral.com/1472-6963/7/177
© 2007 Smeets et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Health Services Research 2007, 7:177 http://www.biomedcentral.com/1472-6963/7/177
Page 2 of 7
(page number not for citation purposes)
Many patients with recurrent dyspeptic or reflux com-
plaints also believe they have to use ASD lifelong [9-13].
Rebound effects and not explicit placebo-effects are addi-
tional factors for patients' pressure for medication. This
calls for GP assisting interventions, aiming at cessation of
chronic ASD use [14-16]. While ASD users consume an
increasing part of the pharmaceutical budget, more effec-
tive use of resources of health care is necessary [17,18].
Better affordable strategies to reduce ASD are required to
stimulate a rational pharmacotherapy.
Traditional strategies of implementation of guidelines,
like passive education or economic measurements to opti-
mise particular prescribing management have proven to
be ineffective [19-21]. Grol et al demonstrated that GPs
need several attributes to comply with recommendations
in guidelines [22-24]. Suggesting that interventions based
on multiple strategies will be more successful when
actively implemented. Earlier reviews of dyspepsia guide-
lines enclosed only studies with single intervention strat-
egies of various backgrounds. Recent reviews also
evaluated combined strategies like audit, feedback or out-
reach visits, but the information provided did not permit
conclusions pertaining the effect on prescription manage-
ment only [25-28]. In this review we systematically evalu-
ate the effectiveness of intervention methods for
implementation of dyspepsia guidelines with the objec-
tive to reduce the volume and costs of ASD prescriptions.
Methods
We performed a systematic literature search from 1995 to
2004 in Medline, Embase and the Cochrane Library which
included search parameters of the following subject head-
ing terms: 'dyspepsia', 'guideline', 'medication', 'imple-
mentation' and 'costs effectiveness'. Furthermore
reference sections in original papers and reviews were
screened to find studies otherwise published.
Selection of studies was done in two stages. In the first
stage studies were screened by titles and abstracts for the
description of involvement in an intervention aimed at
changing management of dyspepsia. In the second stage
the full text of the selected articles was retrieved to proceed
the final selection by two criteria. The first inclusion crite-
rion was that studies met criteria for adequate methodol-
ogy and design. RCT and cohort follow up studies
demonstrating quality criteria of evidence (A, B) set by
Jailwala et al, were considered eligible to be included in
the review [29]. The second inclusion criterion was the
presence of outcome measurements related to reduction
of medication: proportion of patients that stopped; the
number of prescriptions or mean dosage of ASD; effective-
ness of diagnostic tests on prescriptions; prescription costs
or total disease related costs. Finally we classified the dif-
ferences in strategy by which guidelines were imple-
mented in daily clinical care: passive hand-over of
(education) materials (I), or active strategies by a single
(II) or multiple (III) interaction with patients and/or prac-
titioners.
The criteria selection for design and outcome assessment
in the second stage was performed independently by a sec-
ond reviewer (NdeW) and disagreement was resolved by
consensus. Non-systematic studies that did not evaluate
the intervention or did not report outcome measurements
were excluded. After a description of the type of interven-
tion of the included studies, from each study the data per-
taining to the effectiveness of the intervention were
extracted. Outcome figures of prescriptions volume and
costs, as well as the expenditures per patient were analysed
to compare the differences in effects related to the inter-
vention method.
Results
We found 37 articles that met the inclusion criteria, 26 in
the search selection and 8 in the reference sections of stud-
ies. Of these articles, 16 were marked as review articles and
21 represented original research reports (Figure 1).
Seven of the original studies were excluded because they
described guidelines or measured the compliance to
guidelines without reporting relevant outcomes [30-36].
Another three studies were excluded because they were
limited to policy evaluations and one study was excluded
because it described a theoretical model [37-40].
Finally, 10 studies were eligible to be included in analysis
(Table 1) [41-50]. Seven of these studies were designed as
RCT (A2) [43-48,50]. The inclusion of the research popu-
lation and baseline similarity for the intervention was
well described and five of them included intention to treat
analysis, but most studies had shortcomings in reporting
outcomes and statistics.
In the cohort studies (B) the number of involved GPs was
unknown and outcomes were not reported sequentially
and in the multi-centre study (B) was the randomisation
procedure unclear [41,42,49]. None of the B qualified
studies described physicians' involvement in therapy
management and one of them was a direct intervention
from the government [41].
Three of the 10 selected studies did not evaluate cost-effec-
tiveness. One study focused merely on costs. Excluding
the evaluation of governments' intervention on popula-
tion level (unknown numbers of GPs and patients), the
studies involved a total of 847 GPs and/or 3512 patients.BMC Health Services Research 2007, 7:177 http://www.biomedcentral.com/1472-6963/7/177
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Intervention methods
Intervention methods used in these studies were classified
according to three pre-defined strategies. The first category
focused on passive intervention without further imple-
mentation activities on individual patient or doctors level
and enclosed the two cohort studies(I). The first evaluated
the follow up of governmental directives [41]. The second
followed up the revised GP therapy after discontinuing
hospital treatment [49].
The RCTs were included in the two categories of active sin-
gle (II) and active multiple (III) interventions. In the first
category two studies reported effects of guidelines intro-
duced to the physicians by education and consensus
meetings and one study reported effects of a guideline
addressed to patients to reduce themselves medication
[47,48,50]. In the multiple active category most RCTs
reported about GPs who were educated about guidelines
together with active support, feedback or peer visitations
during the intervention [42-46].
The selection process of practitioners and adherence to
the intervention were not clearly reported in all RCT stud-
ies. The duration of the intervention period as well as the
compliance in the groups was not always described sys-
tematically. In general RCTs, reported detailed about the
intervention strategy.
Effect on the number of Prescription and Diagnostic tests
The study on the authorisation program of de government
caused a decrease of 80% of all PPI prescriptions [41]. The
study in which was addressed to patients to reduce their
medication use, ASD prescriptions decreased by 17%
[50]. In the remaining eight GP centred intervention stud-
ies, half of them introduced and promoted H. pylori tests,
while the other half focused on guideline education with
feedback strategies, the effects demonstrated variable out-
comes. In the H. pylori tests group GPs were reinstructed
for treatment, or were activated for using more H. pylori
tests, which resulted in two unknown numbers of less
ASD users and in one number of 31% patients that ceased
ASD use [49,46,42]. The use of more tests caused in one
study more endoscopic referrals. The forth study of this
group invited patient for a H. pylori test, which resulted in
8% less ASD users.
In the guideline and feedback group GPs held consensus
meetings or were given feedback about their prescription
policies, but in three of these studies effects on ASD use
were not reported [47,43,45]. In the fourth study of this
group GPs got a prescription protocol and were exten-
sively visited, what resulted in 40% less ASD users [44].
In general reduction of ASD was not described systemati-
cally, but if so studies with multiple active interventions
demonstrated better results.
Eligible studies assessed in review Figure 1
Eligible studies assessed in review.
Search parameters 37 
Original research 21
Methodological quality 10
RCT 7  Cohort 3 
Reviews 16 
Guideline reports 7
Policy evaluations 3
Theoretical model   1
Outcomes:
Volume 3
Costs    3
Outcomes:
Volume 6
Costs    5BMC Health Services Research 2007, 7:177 http://www.biomedcentral.com/1472-6963/7/177
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Table 1: Studies included in the Review with specifications of implementation strategies and efficacy of treatment and costs
Authors, year Research 
design
Evidence 
quality
Study 
characteristics: 
Population; i+c gr. 
(A) Participants 
(B) Stakeholders 
(C)
Method 
characteristics: 
Intervention type 
(A) Content 
guideline (B) 
Practical 
Attributes (C)
Implementatio
n strategy
Results 
treatment
Results costs
41. Bursey & 
Crowley 2000
Dynamic 
population 
cohort
B A: 110.000 residents 
of NF-land, Canada
B: All GPs
C: Government
A: Authorisation 
program for 
reimbursement.
B: Patient selection 
for PPI use.
C: Algorithm for 
prescription 
management.
I. passive > 80% decrease 
PPI
PPI < 82% ($1.3 
mil) first year; 
<62% after 2 
years.
ASD <36% 
($2.0 mil) first 
year; <16% 
after 2 years
42. Ladabaum & 
Fendrick 2001
Prospective 
multicentre 
trial.
B A: P. ulcer patients 
(54+39)
B: PC-centres (3+3), 
GPs?
C: University 
Michigan.
A: Interactive 
sessions by GE.
B: Test & treat 
strategy
C: H. pylori 
serological test for 
PC.
III. multiple 32% more 
tests; same 
referrals;
31% less 
prescriptions (p 
> .001)
79% in 
intervention 
group ($ 122 
pp) (p = .17)
43. Chan & 
Patel 2001
RCT A2 A: All dyspepsia 
patients
B: GPs (133+146); 
voluntary Hampshire
C: Health authority
A: Posted guidelines 
and reinforcement 
visits by NP
B: Management 
dyspepsia, H pylori.
C: Wall chart, 
booklet
III. multiple - 5% decrease in 
medication
44. Huren-kamp 
& Grund-meijer 
2001
RCT A2 A: H. pylori patients 
(89/85)
B: 48 GP practices, 
voluntary
C: University 
Amsterdam
A: Education of 
protocol; support 
by NP.
B: Tapering 
prescriptions of 
ASD by doses and 
on demand 
treatment.
C: follow up 
patients by NP.
III. multiple Decrease of 1,5 
PDD;
40% stopped 
ASD (ns);
More HP neg, 
more H2RA
-
45. Weynen & 
de Wit 2002
RCT Cluster A2 A: 260 (99/73/88) 
patients
B: 28 GPs; voluntary
C: University 
Utrecht
A: Education 
program, financial 
incentives and 
personal feedback.
B: H. Pylori 
diagnosis and 
treatment
C: Dyspepsia 
questionnaire, HP 
test.
III. multiple 17% better 
follow-up (ns), 
in incentive 
group
Less overall 
costs (€46 pp; 
ns) in incentive 
group
46. Banait & 
Sibbald 2003
RCT cluster, A2 A: Practice 
population (265.000)
B: GP practices 
(57+56); voluntary 
NW England.
C: University, GE, 
Health authorities.
A: Posted guidelines 
with education 
outreach and 
follow-up visit.
B: Clinical strategies 
for referral.
C: Open access to 
endo-scopies and 
serological tests
III. multiple 14% more 
referrals, 4 
more tests/
practice
6% more costs 
ASD
47. Jones & 
Lydeard 1993
RCT, A2 A: Practice 
population (500.000)
B: GPs (78+101); 
voluntary; 
Southampton
C: Consensus group 
GP+GE
A: Consensus 
meetings GP-SP.
B: Investigation and 
refer dyspepsia; 
appropriate use of 
guidelines.
C: reference cards,
II. single No difference 
in referrals and 
endoscopies
22% more 
prescribing 
costsBMC Health Services Research 2007, 7:177 http://www.biomedcentral.com/1472-6963/7/177
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Costs effects
From the cohort studies (I) the authorisation program in
Canada reported 62% sustained decrease of costs for PPI
[41]. The other cohort study and the one with serological
H. pylori tests demonstrated no significant cost effects or
did not report calculations [42,49].
In the studies with single intervention method (II) the
promotion of the dyspepsia protocol resulted in an
increase of 22% ASD costs [47]. The other two studies
demonstrated by involving patients successful reduction
of ASD, but costs effect calculations were not presented
[48,50]. From the multiple intervention methods (III)
three studies demonstrated costs effects varying respec-
tively of 6% increase of ASD costs, no significant changes
of overall medication costs until to 5% decrease in medi-
cation costs [46,45,43].
Calculation of costs in all studies was not done systemat-
ically nor uniform. Sometimes percentages of ASD costs
were given, sometimes the absolute costs and sometimes
none of the two. Some studies reported overall medical
costs, including ASD costs. The different costs calculations
are therefore difficult to compare in this review.
Discussion
There is no doubt that radical changes can be reached
from a governments' intervention, but when doctors
receive a passive mailing or recommendations of key play-
ers to pay more attention to prescription protocols the
effects on the number of prescriptions and costs are disap-
pointing [21]. Studies with more active intervention strat-
egies that support the doctors with recommendations and
visitations had better results.
In studies as identified for this review many of the inter-
ventions were concerned with eradication of H. pylori,
which resulted in small changes of the number of ASD
users or prescriptions. Focussing on positive effects of
ASD reduction and related costs two of the three single
intervention studies (II) demonstrated positive results.
Among the four multiple intervention studies (III) three
reported a positive cost reducing effect. On average this
implies only a modest effect, comparable to the small
effects observed in the earlier Cochrane reviews on the
effects of changes in professional behaviour [26-28].
There was only one study that particularly intervened on
the gradual termination of unnecessary use of ASD [14].
The GPs were recommended to accompany their patients
which resulted in a larger decrease of ASD volumes. How-
ever costs were not calculated.
The overall conclusion is that the number of high-quality
studies on effective interventions for ASD reduction is
limited. In addition the incomparable methods applied to
calculate prescription rates and costs preclude identifica-
tion of the most effective intervention strategies. The latter
can only be achieved after several studies, including simi-
lar outcome measurements evaluating distinct well-
defined interventions, have become available.
Only a few quantitative studies evaluated with varying
success that ASD reduction requires active intervention
strategies with practical instrument for the GP. Grol and
Grimshaw already showed the performance phenomenon
that actual changes in practice depend on helpful
attributes and in particular on attributes that will over-
come identified barriers against changing behaviour
[17,18]. More RCT studies on population level have to cal-
48. Allison & 
Hurley 2003
RCT A2 A: ASD patients 
(321+329).
B: Physicians from 
study
C: HMO California
A: Test & treatment 
random group.
B: T&T protocol
C: Detailed 
instructions
II single Less ulcerlike 
symptoms and 
abdominal pain;
8% less users' 
medication
Higher costs 
because of HP 
treatment (not 
hospital)
49. Kearney & 
Liu 2004
Follow up 
Cohort
B A: ASD patients 
(432)
B: GE from study
C: MHO Seattle
A: Patient Interview 
and HP test
B: Hospital stopped 
ASD medicine
C: Instruction for 
GPs' review.
I. passive 71% ulcer;
29% dyspepsia; 
number 
stopped?
Hospital $34 
less pp;
Medication ns;
Only ulcer 
cases
50. Krol & 
Wensing 2004
RTC cluster A2 A: ASD patients 
(63+50)
B: 20 GP practices 
voluntary
C: University 
Utrecht
A: Direct mail to 
patients to reduce 
ASD.
B: Postal 
instructions for 
patients.
C: Instruction and 
flowchart
II single 17% reduction 
(10% stopped); 
no change in 
symptoms and 
quality
-
Table 1: Studies included in the Review with specifications of implementation strategies and efficacy of treatment and costs (Continued)BMC Health Services Research 2007, 7:177 http://www.biomedcentral.com/1472-6963/7/177
Page 6 of 7
(page number not for citation purposes)
culate more thoroughly the effects that appoint to the par-
ticular successful instruments.
Doctors need rational arguments to get cooperation from
patients. As long as side-effects of long term use of ASD are
unknown and rebound effects make patients afraid to
stop, to negotiate with patients to reduce medication is
not an attractive alternative [12,24].
From this point of view government's interventions like in
Canada, which forces cooperation of patients and doctors
by financial incentives, seems attractive, but sustainability
is questionable [38]. An alternative could be that insur-
ance companies introduce financial rewards, either for the
doctor or the patient, to defeat barriers and enforce their
negotiations. They possible too could facilitate to com-
bine interventions, both practical instruments and finan-
cial compensation, into an effective intervention program
of ASD reduction. Evaluation of these multi-interventions
have to demonstrate which combinations of instruments
fits GPs best.
Conclusion
Studies demonstrate that evidence for effective interven-
tions is limited and cost-effectiveness is often difficult to
compare. Larger multi-intervention studies with similar
outcome measurements and distinct interventions are
needed to evaluate the most successful instruments.
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